{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:02:52Z","timestamp":1794009772725,"version":"4.8.0"},"reference-count":333,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In recent years, \u201cmetabolic dysfunction-associated steatotic liver disease\u201d (MASLD) has been proposed to better connect liver disease to metabolic dysfunction, which is the most common chronic liver disease worldwide. MASLD affects more than 30% of individuals globally, and it is diagnosed by the combination of hepatic steatosis and obesity, type 2 diabetes, or two metabolic risk factors. MASLD begins with the buildup of extra fat, often greater than 5%, within the liver, causing liver hepatocytes to become stressed. This can proceed to a more severe form, metabolic dysfunction-associated steatohepatitis (MASH), in 20\u201330% of people, where inflammation in the liver causes tissue fibrosis, which limits blood flow over time. As fibrosis worsens, MASH may lead to cirrhosis, liver failure, or even liver cancer. While the pathophysiology of MASLD is not fully known, the current \u201cmultiple-hits\u201d concept proposes that dietary and lifestyle factors, metabolic factors, and genetic or epigenetic factors contribute to elevated oxidative stress and inflammation, causing liver fibrosis. This review article provides an overview of the pathogenesis of MASLD and evaluates existing therapies as well as pharmacological drugs that are currently being studied in clinical trials for MASLD or MASH.<\/jats:p>","DOI":"10.3390\/ijms26041778","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:36:22Z","timestamp":1739957782000},"page":"1778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis"],"prefix":"10.3390","volume":"26","author":[{"given":"Arun George","family":"Devasia","sequence":"first","affiliation":[{"name":"Science, Math & Technology, Singapore University of Technology & Design, Singapore 487372, Singapore"},{"name":"Genome Institute of Singapore (GIS), Agency for Science Technology and Research (A*STAR), 60 Biopolis Street, Singapore 138672, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaikalavan","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Genome Institute of Singapore (GIS), Agency for Science Technology and Research (A*STAR), 60 Biopolis Street, Singapore 138672, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-9694","authenticated-orcid":false,"given":"Chen Huei","family":"Leo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, College of Design & Engineering, National University of Singapore, 9 Engineering Drive 1, Singapore 117576, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Boccatonda, A., Andreetto, L., D\u2019Ardes, D., Cocco, G., Rossi, I., Vicari, S., Schiavone, C., Cipollone, F., and Guagnano, M.T. (2023). From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030883"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/RMHP.S285880","article-title":"MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease","volume":"14","author":"Huang","year":"2021","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20420188241242937","DOI":"10.1177\/20420188241242937","article-title":"Gut microbiota in MAFLD: Therapeutic and diagnostic implications","volume":"15","author":"Alghamdi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gabriel-Medina, P., Ferrer-Costa, R., Rodriguez-Frias, F., Ciudin, A., Augustin, S., Rivera-Esteban, J., Peric\u00e0s, J.M., and Selva, D.M. (2022). Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051015"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e20220681","DOI":"10.1084\/jem.20220681","article-title":"Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH","volume":"220","author":"Itoh","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"121542","DOI":"10.1016\/j.lfs.2023.121542","article-title":"Endothelium-dependent relaxation is impaired in Schlager hypertensive (BPH\/2J) mice by region-specific mechanisms in conductance and resistance arteries","volume":"320","author":"Jelinic","year":"2023","journal-title":"Life Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Li, J.C., Velagic, A., Qin, C.X., Li, M., Leo, C.H., Kemp-Harper, B.K., Ritchie, R.H., and Woodman, O.L. (2020). Diabetes Attenuates the Contribution of Endogenous Nitric Oxide but Not Nitroxyl to Endothelium Dependent Relaxation of Rat Carotid Arteries. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.585740"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/ars.2018.7706","article-title":"Nitric Oxide Resistance, Induced in the Myocardium by Diabetes, Is Circumvented by the Nitric Oxide Redox Sibling, Nitroxyl","volume":"32","author":"Qin","year":"2020","journal-title":"Antioxid. Redox Signal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/bph.14927","article-title":"Annexin-A1 deficiency exacerbates pathological remodelling of the mesenteric vasculature in insulin-resistant, but not insulin-deficient, mice","volume":"177","author":"Jelinic","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Leo, C.H., Foo, S.Y., Tan, J.C.W., Tan, U.X., Chua, C.K., and Ong, E.S. (2022). Green Extraction of Orange Peel Waste Reduces TNF\u03b1-Induced Vascular Inflammation and Endothelial Dysfunction. Antioxidants, 11.","DOI":"10.3390\/antiox11091768"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ong, E.S., Low, J., Tan, J.C.W., Foo, S.Y., and Leo, C.H. (2022). Valorization of avocado seeds with antioxidant capacity using pressurized hot water extraction. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-17326-5"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ong, E.S., Oh, C.L.Y., Tan, J.C.W., Foo, S.Y., and Leo, C.H. (2021). Pressurized Hot Water Extraction of Okra Seeds Reveals Antioxidant, Antidiabetic and Vasoprotective Activities. Plants, 10.","DOI":"10.3390\/plants10081645"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study","volume":"155","author":"Castellanos","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.13973","article-title":"Cardiovascular risk factors in non-alcoholic fatty liver disease","volume":"39","author":"Nasr","year":"2019","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., and Zhang, Z. (2016). Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci. Rep., 6.","DOI":"10.1038\/srep33386"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis: An Overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hydes, T., Alam, U., and Cuthbertson, D.J. (2021). The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.640557"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3350\/cmh.2022.0237","article-title":"Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41430-022-01225-z","article-title":"Ultra-processed foods and the development of obesity in adults","volume":"77","author":"Harb","year":"2023","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.14360","article-title":"The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management","volume":"40","year":"2020","journal-title":"Liver Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Detopoulou, P., Dedes, V., Syka, D., Tzirogiannis, K., and Panoutsopoulos, G.I. (2023). Relation of Minimally Processed Foods and Ultra-Processed Foods with the Mediterranean Diet Score, Time-Related Meal Patterns and Waist Circumference: Results from a Cross-Sectional Study in University Students. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20042806"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1753-4887.2009.00246.x","article-title":"Choline: An essential nutrient for public health","volume":"67","author":"Zeisel","year":"2009","journal-title":"Nutr. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41430-023-01336-1","article-title":"Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017\u20132018","volume":"77","author":"Chai","year":"2023","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, X., Qiu, W., Ma, X., Ren, L., Feng, M., Hu, S., Xue, C., and Chen, R. (2024). Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers. Front. Biosci. (Landmark Ed.), 29.","DOI":"10.31083\/j.fbl2905182"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DMSO.S146339","article-title":"Obesity and nonalcoholic fatty liver disease: Current perspectives","volume":"11","author":"Sarwar","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3727\/105221617X15124844266408","article-title":"The Effects of Physical Exercise on Fatty Liver Disease","volume":"18","author":"Sud","year":"2018","journal-title":"Gene Expr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.3350\/cmh.2022.0393","article-title":"The effects of moderate alcohol consumption on non-alcoholic fatty liver disease","volume":"29","author":"Oh","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00417","DOI":"10.14309\/ctg.0000000000000417","article-title":"Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study","volume":"12","author":"Um","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/jpgm.JPGM_140_17","article-title":"Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"63","author":"Wijarnpreecha","year":"2017","journal-title":"J. Postgrad. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.plefa.2010.02.012","article-title":"Fatty liver: Role of inflammation and fatty acid nutrition","volume":"82","author":"Byrne","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11011-011-9269-3","article-title":"Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy","volume":"27","author":"Felipo","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11011-006-9042-1","article-title":"Role of ammonia and inflammation in minimal hepatic encephalopathy","volume":"22","author":"Shawcross","year":"2007","journal-title":"Metab. Brain Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100780","DOI":"10.1016\/j.jhepr.2023.100780","article-title":"Role of ammonia in NAFLD: An unusual suspect","volume":"5","author":"Thomsen","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrgastro.2017.35","article-title":"NAFLD: A critical role for the NLRP3 inflammasome in NASH","volume":"14","author":"Thomas","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Luci, C., Bourinet, M., Lecl\u00e8re, P.S., Anty, R., and Gual, P. (2020). Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.597648"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","article-title":"Mechanisms of hepatic fibrogenesis","volume":"25","author":"Lee","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1535370219898141","article-title":"Mechanisms of liver fibrosis and its role in liver cancer","volume":"245","author":"Dhar","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1570161119666210628125239","article-title":"Association of PAF and its Metabolic Enzymes with GGT and the Fatty Liver Index in Healthy Volunteers","volume":"19","author":"Detopoulou","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.2147\/DMSO.S367483","article-title":"Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease","volume":"15","author":"Yin","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","article-title":"Heritability of nonalcoholic fatty liver disease","volume":"136","author":"Schwimmer","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40001-024-01708-8","article-title":"Exploring the role of genetic variations in NAFLD: Implications for disease pathogenesis and precision medicine approaches","volume":"29","author":"Mahmoudi","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11154-020-09621-1","article-title":"Lean NAFLD: An underrecognized and challenging disorder in medicine","volume":"22","author":"Maier","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.28283","article-title":"Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study","volume":"63","author":"Goffredo","year":"2016","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Xu, Q.Y., Li, H., Cao, H.X., Pan, Q., and Fan, J.G. (2020). APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. BioMed Res. Int., 2020.","DOI":"10.1155\/2020\/8869674"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"20420188221132138","DOI":"10.1177\/20420188221132138","article-title":"Update on genetics and epigenetics in metabolic associated fatty liver disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1055\/s-0030-1267186","article-title":"A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis","volume":"42","author":"Auinger","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/liv.14039","article-title":"The immunity-related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study","volume":"39","author":"Simon","year":"2019","journal-title":"Liver Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jhep.2017.02.037","article-title":"The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children","volume":"67","author":"Bellini","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2011.05.029","article-title":"The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies","volume":"56","author":"Anstee","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JCMA.0000000000000437","article-title":"Genetic variations of three important antioxidative enzymes SOD2, CAT, and GPX1 in nonalcoholic steatohepatitis","volume":"84","author":"Huang","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease","volume":"378","author":"Cheng","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12072-024-10667-5","article-title":"The contribution of genetics and epigenetics to MAFLD susceptibility","volume":"18","author":"Moretti","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"154809","DOI":"10.1016\/j.prp.2023.154809","article-title":"A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression","volume":"251","author":"Ramezani","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zaiou, M., Amrani, R., Rihn, B., and Hajri, T. (2021). Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091256"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Purcell, A.R., and Glastras, S.J. (2023). Maternal Weight Management to Prevent the Developmental Programming of MAFLD in Offspring of Obese Mothers. Nutrients, 15.","DOI":"10.3390\/nu15092155"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.14218\/JCTH.2022.00052","article-title":"Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update","volume":"10","author":"Fouda","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/hep.23205","article-title":"Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression","volume":"50","author":"Bruce","year":"2009","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1210\/jc.2013-3199","article-title":"Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood","volume":"99","author":"Breij","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc07-0281","article-title":"Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children","volume":"30","author":"Nobili","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2016.05.020","article-title":"Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study","volume":"65","author":"Suomela","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jhep.2016.06.010","article-title":"Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood","volume":"65","author":"Valenti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Dudley, K.J., Sloboda, D.M., Connor, K.L., Beltrand, J., and Vickers, M.H. (2011). Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021662"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"15538","DOI":"10.1073\/pnas.1412759111","article-title":"Obesity accelerates epigenetic aging of human liver","volume":"111","author":"Horvath","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","article-title":"Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease","volume":"62","author":"Pirola","year":"2013","journal-title":"Gut"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/hep.23927","article-title":"Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation of the peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 promoter","volume":"52","author":"Sookoian","year":"2010","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12986-021-00600-0","article-title":"Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice","volume":"18","author":"Kazeminasab","year":"2021","journal-title":"Nutr. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"958","DOI":"10.4239\/wjd.v14.i7.958","article-title":"Novel insights regarding the role of noncoding RNAs in diabetes","volume":"14","author":"Macvanin","year":"2023","journal-title":"World J. Diabetes"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e13203","DOI":"10.1111\/obr.13203","article-title":"Role of long non-coding RNAs in adipogenesis: State of the art and implications in obesity and obesity-associated diseases","volume":"22","author":"Rey","year":"2021","journal-title":"Obes. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101581","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Sulaiman, S.A., Muhsin, N.I.A., and Jamal, R. (2019). Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00279"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","article-title":"Long non-coding RNAs: Definitions, functions, challenges and recommendations","volume":"24","author":"Mattick","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","article-title":"Circular RNA: Metabolism, functions and interactions with proteins","volume":"19","author":"Zhou","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Xiao, J., Joseph, S., Xia, M., Teng, F., Chen, X., Huang, R., Zhai, L., and Deng, W. (2022). Circular RNAs Acting as miRNAs\u2019 Sponges and Their Roles in Stem Cells. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102909"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/hep.30577","article-title":"The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis","volume":"70","author":"Mehal","year":"2019","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","article-title":"Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease","volume":"68","author":"Chu","year":"2019","journal-title":"Gut"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.26319","article-title":"Intestinal microbiota in patients with nonalcoholic fatty liver disease","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","article-title":"Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease","volume":"69","author":"Sookoian","year":"2020","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1172\/JCI94601","article-title":"l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans","volume":"129","author":"Koeth","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Chen, Y.M., Liu, Y., Zhou, R.F., Chen, X.L., Wang, C., Tan, X.Y., Wang, L.J., Zheng, R.D., Zhang, H.W., and Ling, W.H. (2016). Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep., 6.","DOI":"10.1038\/srep19076"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e1900257","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Shanmugham, M., Bellanger, S., and Leo, C.H. (2023). Gut-Derived Metabolite, Trimethylamine-N-oxide (TMAO) in Cardio-Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040504"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Shanmugham, M., Devasia, A.G., Chin, Y.L., Cheong, K.H., Ong, E.S., Bellanger, S., Ramasamy, A., and Leo, C.H. (2023). Time-dependent specific molecular signatures of inflammation and remodelling are associated with trimethylamine-N-oxide (TMAO)-induced endothelial cell dysfunction. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-46820-7"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Tan, S.S.Y., Shanmugham, M., Chin, Y.L., An, J., Chua, C.K., Ong, E.S., and Leo, C.H. (2023). Pressurized Hot Water Extraction of Mangosteen Pericarp and Its Associated Molecular Signatures in Endothelial Cells. Antioxidants, 12.","DOI":"10.3390\/antiox12111932"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2018.09.055","article-title":"Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1","volume":"175","author":"Koh","year":"2018","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jcmgh.2016.04.007","article-title":"Hepatocyte Toll-Like Receptor 5 Promotes Bacterial Clearance and Protects Mice Against High-Fat Diet-Induced Liver Disease","volume":"2","author":"Gewirtz","year":"2016","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12072-013-9468-6","article-title":"Immune and inflammatory pathways in NASH","volume":"7","author":"Ganz","year":"2013","journal-title":"Hepatol. Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.271.5249.665","article-title":"IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance","volume":"271","author":"Hotamisligil","year":"1996","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature18846","article-title":"Diet-microbiota interactions as moderators of human metabolism","volume":"535","author":"Sonnenburg","year":"2016","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2014.12.036","article-title":"Food, immunity, and the microbiome","volume":"148","author":"Tilg","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Kessoku, T., Kobayashi, T., Imajo, K., Tanaka, K., Yamamoto, A., Takahashi, K., Kasai, Y., Ozaki, A., Iwaki, M., and Nogami, A. (2021). Endotoxins and Non-Alcoholic Fatty Liver Disease. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.770986"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1053\/j.gastro.2012.01.034","article-title":"A high-fat diet is associated with endotoxemia that originates from the gut","volume":"142","author":"Pendyala","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_106","unstructured":"Pfizer (2024, September 12). A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety, Tolerability, and Pharmacodynamics of PF-05221304 Administered Daily for 16-weeks to Adult Subjects with Nonalcoholic Fatty Liver Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03248882."},{"key":"ref_107","unstructured":"Pfizer (2024, September 12). A Study to Assess Pharmacodynamics, Safety and Tolerability of PF-05221304 and PF-06865571 Co-Administered for 6 Weeks In Adults with Non-Alcoholic Fatty Liver Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03776175."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"eabg8116","DOI":"10.1126\/scitranslmed.abg8116","article-title":"A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/13543784.2023.2230115","article-title":"Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)","volume":"32","author":"Puengel","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e00329","DOI":"10.1002\/prp2.329","article-title":"Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes","volume":"5","author":"Zhang","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_115","first-page":"S46","article-title":"Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status","volume":"12","author":"Roy","year":"2022","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"ref_116","unstructured":"NIDDK (2024, September 12). The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial (FLINT), Available online: https:\/\/clinicaltrials.gov\/study\/NCT01265498."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic Acid: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cld.1076","article-title":"Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis","volume":"17","author":"Ratziu","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(19)32963-0","article-title":"Obeticholic acid: Towards first approval for NASH","volume":"394","author":"Eslam","year":"2019","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated with the Antioxidative Gene Expression Profile in Rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_122","unstructured":"Novartis Pharmaceuticals (2024, September 12). Study of Safety and Efficacy of Tropifexor (LJN452) in Patients with Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02855164."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients with Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Schwabl, P., Hambruch, E., Budas, G.R., Supper, P., Burnet, M., Liles, J.T., Birkel, M., Brusilovskaya, K., K\u00f6nigshofer, P., and Peck-Radosavljevic, M. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010060"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_130","first-page":"1267A","article-title":"In vitro and in vivo characterization of EYP001, a novel, potent and selective FXR agonist now in a Phase 2 clinical trial in NASH","volume":"70","author":"Radreau","year":"2019","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_132","unstructured":"Enyo Pharma (2024, September 12). Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients with Nonalcoholic Steatohepatitis (NASH), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03812029."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, \u03b2-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV. Endocrinol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_136","unstructured":"Madrigal Pharmaceuticals, Inc (2024, September 11). Phase 2 Study of MGL-3196 in Patients with Non-Alcoholic Steatohepatitis (NASH), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02912260."},{"key":"ref_137","unstructured":"Madrigal Pharmaceuticals, Inc (2024, September 11). A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04197479."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_140","unstructured":"Madrigal Pharmaceuticals, Inc (2024, September 12). A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients with NASH and Fibrosis (MAESTRO-NASH), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03900429."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_144","unstructured":"Inventiva Pharma (2024, September 13). A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients with (NASH) and Fibrosis Stages F2 and F3 (NATiV3) (NATiV3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04849728."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"van den Hoek, A.M., Verschuren, L., Caspers, M.P.M., Worms, N., Menke, A.L., and Princen, H.M.G. (2021). Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-83974-8"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients","volume":"12","author":"Padole","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Honda, Y., Kessoku, T., Ogawa, Y., Tomeno, W., Imajo, K., Fujita, K., Yoneda, M., Takizawa, T., Saito, S., and Nagashima, Y. (2017). Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci. Rep., 7.","DOI":"10.1038\/srep42477"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Sasaki, Y., Asahiyama, M., Tanaka, T., Yamamoto, S., Murakami, K., Kamiya, W., Matsumura, Y., Osawa, T., Anai, M., and Fruchart, J.C. (2020). Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-64902-8"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e00700","DOI":"10.1002\/prp2.700","article-title":"Dexmedetomidine ameliorates high-fat diet-induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice","volume":"9","author":"Tao","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_153","unstructured":"Ionis Pharmaceuticals (2024, September 13). ION839. Available online: https:\/\/www.ionis.com\/medicines\/ionis-az6-2-5-lrxazd2693\/."},{"key":"ref_154","unstructured":"AstraZeneca (2024, September 13). A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis (FORTUNA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05809934."},{"key":"ref_155","unstructured":"Ionis Pharmaceuticals (2024, September 13). ION224. Available online: https:\/\/www.ionis.com\/medicines\/ion224\/."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"ref_159","unstructured":"Ionis Pharmaceuticals (2024, September 13). Ionis Announces Positive Results from Phase 2 Study of ION224, an Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH\/MASH. Available online: https:\/\/ir.ionis.com\/news-releases\/news-release-details\/ionis-announces-positive-results-phase-2-study-ion224."},{"key":"ref_160","unstructured":"Ionis Pharmaceuticals (2024, September 13). A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04932512."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00125-012-2511-7","article-title":"Serine\/threonine protein kinase 25 (STK25): A novel negative regulator of lipid and glucose metabolism in rodent and human skeletal muscle","volume":"55","author":"Nerstedt","year":"2012","journal-title":"Diabetologia"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jcmgh.2018.12.004","article-title":"Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease","volume":"7","author":"Cansby","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_163","unstructured":"Sprint Bioscience (2024, September 13). STK25. Available online: https:\/\/sprintbioscience.com\/en\/pipeline\/internal-programs\/#stk25."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_165","unstructured":"Arrowhead Pharmaceuticals (2024, September 13). Study of ARO-HSD in Healthy Volunteers and Patients with Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04202354."},{"key":"ref_166","unstructured":"AstraZeneca (2024, September 13). A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05143905."},{"key":"ref_167","unstructured":"AstraZeneca (2024, September 13). Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05560607."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_169","unstructured":"Gilead Sciences (2024, September 14). Safety and Efficacy of Selonsertib in Adults with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03053050."},{"key":"ref_170","unstructured":"Gilead Sciences (2024, September 14). Safety and Efficacy of Selonsertib in Adults with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03053063."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5551\/jat.3368","article-title":"C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice","volume":"17","author":"Tamura","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Lefebvre, E., Moyle, G., Reshef, R., Richman, L.P., Thompson, M., Hong, F., Chou, H.L., Hashiguchi, T., Plato, C., and Poulin, D. (2016). Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_175","unstructured":"Galectin Therapeutics Inc (2024, September 14). Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04365868."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Cagnoni","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease","volume":"65","author":"Zetterberg","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_178","unstructured":"Galecto Biotech AB (2024, September 14). A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants with Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04607655."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e12464","DOI":"10.1111\/micc.12464","article-title":"From pregnancy to cardiovascular disease: Lessons from relaxin-deficient animals to understand relaxin actions in the vascular system","volume":"26","author":"Jelinic","year":"2019","journal-title":"Microcirculation"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"R753","DOI":"10.1152\/ajpregu.00276.2017","article-title":"Peptide hormone relaxin: From bench to bedside","volume":"314","author":"Jelinic","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Leo, C.H., Fernando, D.T., Tran, L., Ng, H.H., Marshall, S.A., and Parry, L.J. (2017). Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00141"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/bph.13614","article-title":"Vascular actions of relaxin: Nitric oxide and beyond","volume":"174","author":"Leo","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bph.14858","article-title":"Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights","volume":"177","author":"Leo","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Leo, C.H., Ou, J.L.M., Ong, E.S., Qin, C.X., Ritchie, R.H., Parry, L.J., and Ng, H.H. (2023). Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice. Biomed. Pharmacother., 162.","DOI":"10.1016\/j.biopha.2023.114578"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Devasia, A.G., Shanmugham, M., Ramasamy, A., Bellanger, S., Parry, L.J., and Leo, C.H. (2024). Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes. Biochem. Pharmacol., 229.","DOI":"10.1016\/j.bcp.2024.116507"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coph.2019.04.001","article-title":"Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases","volume":"45","author":"Leo","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.tips.2016.04.001","article-title":"Serelaxin: A Novel Therapeutic for Vascular Diseases","volume":"37","author":"Leo","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Ng, H.H., Leo, C.H., Parry, L.J., and Ritchie, R.H. (2018). Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00501"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.12247","article-title":"Relaxin decreases the severity of established hepatic fibrosis in mice","volume":"34","author":"Bennett","year":"2014","journal-title":"Liver Int."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep.26627","article-title":"Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo","volume":"59","author":"Fallowfield","year":"2014","journal-title":"Hepatology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41374-019-0240-y","article-title":"Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease","volume":"99","author":"Lee","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"McBride, A., Hoy, A.M., Bamford, M.J., Mossakowska, D.E., Ruediger, M.P., Griggs, J., Desai, S., Simpson, K., Caballero-Hernandez, I., and Iredale, J.P. (2017). In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-10521-9"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"12435","DOI":"10.1096\/fj.201901046R","article-title":"Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis","volume":"33","author":"Kaftanovskaya","year":"2019","journal-title":"FASEB J."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","article-title":"Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis","volume":"16","author":"Hu","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Snowdon, V.K., Lachlan, N.J., Hoy, A.M., Hadoke, P.W., Semple, S.I., Patel, D., Mungall, W., Kendall, T.J., Thomson, A., and Lennen, R.J. (2017). Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002248"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bcp.12572","article-title":"Pharmacokinetics of serelaxin in patients with hepatic impairment: A single-dose, open-label, parallel group study","volume":"79","author":"Kobalava","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/biolre\/iox023","article-title":"Relaxin treatment reduces angiotensin II-induced vasoconstriction in pregnancy and protects against endothelial dysfunction\u2020","volume":"96","author":"Marshall","year":"2017","journal-title":"Biol. Reprod."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2017.05.005","article-title":"B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin)","volume":"807","author":"Marshall","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.phrs.2016.03.011","article-title":"Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta","volume":"107","author":"Ng","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Ng, H.H., Leo, C.H., Prakoso, D., Qin, C., Ritchie, R.H., and Parry, L.J. (2017). Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes. Sci. Rep., 7.","DOI":"10.1038\/srep39604"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40265-018-1020-5","article-title":"L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease","volume":"79","author":"Canbay","year":"2019","journal-title":"Drugs"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.29107","article-title":"Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis","volume":"65","author":"Kumar","year":"2017","journal-title":"Hepatology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/A:1020613314572","article-title":"L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action","volume":"13","author":"Rose","year":"1998","journal-title":"Metab. Brain Dis."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3892\/etm.2013.1434","article-title":"Effects of glutamine on oxidative stress and nuclear factor-\u03baB expression in the livers of rats with nonalcoholic fatty liver disease","volume":"7","author":"Lin","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.3945\/jn.115.215517","article-title":"Oral Glutamine Supplementation Protects Female Mice from Nonalcoholic Steatohepatitis","volume":"145","author":"Sellmann","year":"2015","journal-title":"J. Nutr."},{"key":"ref_206","first-page":"219","article-title":"Efficacy of L-ornithin-L-aspartate-granules in chronic liver diseases","volume":"52","author":"Grungreiff","year":"2001","journal-title":"Med. Welt Stuttg."},{"key":"ref_207","first-page":"528","article-title":"Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: A multiple-dose parallel controlled clinical trial","volume":"21","author":"Tian","year":"2013","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Ermolova, T., and Ermolov, S. (2018). Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients. \u0413\u0430\u0441\u0442\u0440o\u044d\u043d\u0442\u0435\u0440o\u043b. \u0421\u0430\u043d\u043a\u0442-\u041f\u0435\u0442\u0435\u0440\u0431\u0443\u0440\u0433\u0430, 108\u2013109.","DOI":"10.1016\/S0168-8278(18)31432-6"},{"key":"ref_209","first-page":"498","article-title":"Liraglutide (victoza): The first once-daily incretin mimetic injection for type-2 diabetes","volume":"35","author":"Jackson","year":"2010","journal-title":"Pharm. Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"Birkenfeld","year":"2018","journal-title":"Lancet"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/oby.22462","article-title":"Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada","volume":"27","author":"Wharton","year":"2019","journal-title":"Obesity"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.12659\/MSM.907227","article-title":"Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic \u03b2-Cell Function in db\/db Mice","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_214","first-page":"8316","article-title":"Liraglutide reduces hepatic glucolipotoxicity-induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats","volume":"17","author":"Guo","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Khalifa, O., Al-Akl, N.S., Errafii, K., and Arredouani, A. (2022). Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt\/-catenin signaling pathway. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-06143-5"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Soto-Catal\u00e1n, M., Opazo-R\u00edos, L., Quiceno, H., L\u00e1zaro, I., Moreno, J.A., G\u00f3mez-Guerrero, C., Egido, J., and Mas-Fontao, S. (2024). Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052961"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"101922","DOI":"10.1016\/j.clinre.2022.101922","article-title":"The mTORC1\/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice","volume":"46","author":"Marinho","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Wu, L., Zhan, Y., and Wang, Y. (2024). Semaglutide May Ameliorate Fibrosis and Inhibit Epithelial-Mesenchymal Transition in Intrauterine Adhesion Models. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25116196"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Mao, T., Zhang, C., Yang, S., Bi, Y., Li, M., and Yu, J. (2024). Semaglutide alters gut microbiota and improves NAFLD in db\/db mice. Biochem. Biophys. Res. Commun., 710.","DOI":"10.1016\/j.bbrc.2024.149882"},{"key":"ref_221","first-page":"52","article-title":"The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes","volume":"96","author":"Ruda","year":"2023","journal-title":"Med. Pharm. Rep."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: A post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-016-0985-7","article-title":"The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism","volume":"14","author":"Andreozzi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41366-019-0513-y","article-title":"Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice","volume":"44","author":"Xu","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Ionut, V., Woolcott, O.O., Mkrtchyan, H.J., Stefanovski, D., Kabir, M., Iyer, M.S., Liu, H., Castro, A.V., Wu, Q., and Broussard, J.L. (2016). Exenatide Treatment Alone Improves \u03b2-Cell Function in a Canine Model of Pre-Diabetes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158703"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_229","unstructured":"AstraZeneca (2024, September 15). Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01144338."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","article-title":"Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway","volume":"195","author":"Lu","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jcpt.13521","article-title":"Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials","volume":"47","author":"Wu","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Xu, J., Hirai, T., Koya, D., and Kitada, M. (2021). Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010137"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nyas.12852","article-title":"Canagliflozin: A sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"1358","author":"Rosenthal","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.2147\/DDDT.S388823","article-title":"Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice","volume":"16","author":"Zuo","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.5551\/jat.52100","article-title":"Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice","volume":"27","author":"Rahadian","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Li, L., Li, Q., Huang, W., Han, Y., Tan, H., An, M., Xiang, Q., Zhou, R., Yang, L., and Cheng, Y. (2021). Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.589273"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"174304","DOI":"10.1016\/j.ejphar.2021.174304","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","volume":"907","author":"Luo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.D., Kyrou, I., Efstathopoulos, E., Randeva, H.S., and Kassi, E. (2022). SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063107"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4239\/wjd.v6.i1.136","article-title":"Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan","volume":"6","author":"Ohkura","year":"2015","journal-title":"World J. Diabetes"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Salim, H.M., Fukuda, D., Yagi, S., Soeki, T., Shimabukuro, M., and Sata, M. (2016). Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Front. Cardiovasc. Med., 3.","DOI":"10.3389\/fcvm.2016.00043"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12933-024-02149-7","article-title":"Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: The SUCRE study","volume":"23","author":"Nagao","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/dom.14448","article-title":"Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin","volume":"23","author":"Kaku","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3350\/cmh.2020.0125","article-title":"Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis","volume":"27","author":"Lee","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Carpi, R.Z., Barbalho, S.M., Sloan, K.P., Laurindo, L.F., Gonzaga, H.F., Grippa, P.C., Zutin, T.L.M., Girio, R.J.S., Repetti, C.S.F., and Detregiachi, C.R.P. (2022). The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158805"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e26991","DOI":"10.1016\/j.heliyon.2024.e26991","article-title":"Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: Hit multiple targets with a single shot","volume":"30","author":"Mousa","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.dld.2023.06.015","article-title":"Fecal microbiota transplantation improves hepatic fibro-inflammation via regulating oxidative stress in experimental NASH","volume":"55","author":"Lee","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Zhou, D., Pan, Q., Shen, F., Cao, H.X., Ding, W.J., Chen, Y.W., and Fan, J.G. (2017). Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-01751-y"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Vidal-Cevallos, P., Mur\u00faa-Beltr\u00e1n Gall, S., Uribe, M., and Ch\u00e1vez-Tapia, N.C. (2023). Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914605"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nm.2207","article-title":"Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance","volume":"16","author":"Varela","year":"2010","journal-title":"Nat. Med."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1210\/en.2006-0116","article-title":"Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone","volume":"147","author":"Hashimoto","year":"2006","journal-title":"Endocrinology"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"e056159","DOI":"10.1136\/bmjopen-2021-056159","article-title":"Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): Rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Aaldijk, A.S., Verzijl, C.R.C., Jonker, J.W., and Struik, D. (2023). Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1150222"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: In NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Henriksson, E., and Andersen, B. (2020). FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.601349"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1194\/jlr.M700351-JLR200","article-title":"FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption","volume":"48","author":"Jung","year":"2007","journal-title":"J. Lipid Res."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1534-5807(02)00154-5","article-title":"Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis","volume":"2","author":"Kerr","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1096\/fj.11-195701","article-title":"Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition","volume":"26","author":"Renga","year":"2012","journal-title":"FASEB J."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S207277","article-title":"The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_271","unstructured":"Novartis Pharmaceuticals (2024, September 12). Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients with NASH and Liver Fibrosis (TANDEM), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03517540."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Wagner, N., and Wagner, K.D. (2020). The Role of PPARs in Disease. Cells, 9.","DOI":"10.3390\/cells9112367"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-11488-6_3","article-title":"Understanding Peroxisome Proliferator-Activated Receptors: From the Structure to the Regulatory Actions on Metabolism","volume":"1127","author":"Ferreira","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"106786","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular Actions of PPAR\u03b1 in Lipid Metabolism and Inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr. Rev."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"572405","DOI":"10.1155\/2010\/572405","article-title":"Role of PPAR\u03b1 in Hepatic Carbohydrate Metabolism","volume":"2010","author":"Peeters","year":"2010","journal-title":"PPAR Res."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Palomer, X., Barroso, E., Pizarro-Delgado, J., Pe\u00f1a, L., Botteri, G., Zarei, M., Aguilar, D., Montori-Grau, M., and V\u00e1zquez-Carrera, M. (2018). PPAR\u03b2\/\u03b4: A Key Therapeutic Target in Metabolic Disorders. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030913"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-2275(20)30159-0","article-title":"PPARadigms and PPARadoxes: Expanding roles for PPARgamma in the control of lipid metabolism","volume":"43","author":"Walczak","year":"2002","journal-title":"J. Lipid Res."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Sun, C., Mao, S., Chen, S., Zhang, W., and Liu, C. (2021). PPARs-Orchestrated Metabolic Homeostasis in the Adipose Tissue. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168974"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Kamata, S., Honda, A., and Ishii, I. (2023). Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Biomolecules, 13.","DOI":"10.3390\/biom13081264"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4254\/wjh.v14.i1.168","article-title":"Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence","volume":"14","author":"Jeyakumar","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1073\/pnas.0401627101","article-title":"Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver","volume":"101","author":"Dobrzyn","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"30132","DOI":"10.1074\/jbc.M005488200","article-title":"The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1","volume":"275","author":"Miyazaki","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"15338","DOI":"10.1096\/fj.202000836RR","article-title":"N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPAR\u03b1 and SCD-1","volume":"34","author":"Zhang","year":"2020","journal-title":"FASEB J."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2337\/db06-1142","article-title":"Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice","volume":"56","author":"Flowers","year":"2007","journal-title":"Diabetes"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1172\/JCI200523962","article-title":"Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1","volume":"115","author":"Jiang","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2020.01.143","article-title":"MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1","volume":"524","author":"Zhang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1530\/JME-16-0179","article-title":"miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1","volume":"59","author":"Guo","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Zhang, M., Sun, W., Zhou, M., and Tang, Y. (2017). MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-15141-x"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1248\/bpb.b12-00702","article-title":"A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis","volume":"36","author":"Kurikawa","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/dgd.12255","article-title":"Hepatocyte differentiation of human induced pluripotent stem cells is modulated by stearoyl-CoA desaturase 1 activity","volume":"57","author":"Rahimi","year":"2015","journal-title":"Dev. Growth Differ."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ejmech.2018.09.003","article-title":"Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity","volume":"158","author":"Iida","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2009.07.004","article-title":"Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models","volume":"618","author":"Issandou","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Ahnmark","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"102184","DOI":"10.1016\/j.omtn.2024.102184","article-title":"Oligonucleotide therapies for nonalcoholic steatohepatitis","volume":"35","author":"Li","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17474124.2019.1570136","article-title":"Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease","volume":"13","author":"Kefala","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: A matter of life and death","volume":"15","author":"Schwabe","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00018-016-2161-x","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"73","author":"Liu","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2183\/pjab.88.434","article-title":"Therapeutic targets in the ASK1-dependent stress signaling pathways","volume":"88","author":"Hayakawa","year":"2012","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.108.112292","article-title":"Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition","volume":"52","author":"Yamamoto","year":"2008","journal-title":"Hypertension"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"170","DOI":"10.37349\/emed.2020.00012","article-title":"The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis","volume":"1","author":"Doulberis","year":"2020","journal-title":"Explor. Med."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","article-title":"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2","volume":"44","author":"Haukeland","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"G1310-21","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/apt.14210","article-title":"Review article: New treatments in non-alcoholic fatty liver disease","volume":"46","author":"Townsend","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: Unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"key":"ref_310","doi-asserted-by":"crossref","unstructured":"Traber, P.G., and Zomer, E. (2013). Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083481"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/17512433.2021.1894127","article-title":"Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Antaramian","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Dings, R.P.M., Miller, M.C., Griffin, R.J., and Mayo, K.H. (2018). Galectins as Molecular Targets for Therapeutic Intervention. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030905"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-022-05181-1","article-title":"Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling","volume":"13","author":"Bai","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4254\/wjh.v15.i2.201","article-title":"Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis","volume":"15","author":"Kram","year":"2023","journal-title":"World J. Hepatol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.3892\/ijo.2015.2941","article-title":"Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo","volume":"46","author":"Fujita","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"G439","DOI":"10.1152\/ajpgi.00257.2011","article-title":"Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo","volume":"302","author":"Jiang","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"de Oliveira, F.L., Panera, N., De Stefanis, C., Mosca, A., D\u2019Oria, V., Crudele, A., De Vito, R., Nobili, V., and Alisi, A. (2019). The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143460"},{"key":"ref_319","doi-asserted-by":"crossref","unstructured":"Coelho, I., Duarte, N., Barros, A., Macedo, M.P., and Penha-Gon\u00e7alves, C. (2020). Trem-2 Promotes Emergence of Restorative Macrophages and Endothelial Cells During Recovery from Hepatic Tissue Damage. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.616044"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-0716-2128-8_15","article-title":"Single Cell RNA Sequencing in NASH","volume":"2455","author":"Hundertmark","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Nevola, R., Pafundi, P.C., Monaco, L., Ricozzi, C., Imbriani, S., Rinaldi, L., and Sasso, F.C. (2019). Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. Nutrients, 11.","DOI":"10.3390\/nu11081878"},{"key":"ref_322","doi-asserted-by":"crossref","unstructured":"Green, C.J., Henriksen, T.I., Pedersen, B.K., and Solomon, T.P. (2012). Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044284"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12020-007-9011-4","article-title":"GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes","volume":"32","author":"Gao","year":"2007","journal-title":"Endocrine"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_325","doi-asserted-by":"crossref","unstructured":"Alobaid, S.M., Alshahrani, R.M., Alonazi, A.S., Alrasheed, N.M., Alamin, M.A., Alshammari, T.K., Bin Dayel, A.F., Elnagar, D.M., Alotaibi, R.R., and Almuthnabi, L.A. (2024). Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK\/PI3K\/AKT\/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030374"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/hepr.12837","article-title":"Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s13300-020-00839-5","article-title":"Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review","volume":"11","author":"Robinson","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"9926462","DOI":"10.1155\/2023\/9926462","article-title":"Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts","volume":"2023","author":"Deng","year":"2023","journal-title":"Int. J. Endocrinol."},{"key":"ref_329","unstructured":"Padda, I.S., Mahtani, A.U., and Parmar, M. (2022). Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors, StatPearls."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.31115","article-title":"Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase\/Fructose-2,6-Biphosphatase 3","volume":"72","author":"Ma","year":"2020","journal-title":"Hepatology"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cmet.2018.01.005","article-title":"An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans","volume":"27","author":"Mardinoglu","year":"2018","journal-title":"Cell Metab."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2019-320438","article-title":"Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake","volume":"69","author":"Meslier","year":"2020","journal-title":"Gut"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:38:04Z","timestamp":1760027884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":333,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26041778"],"URL":"https:\/\/doi.org\/10.3390\/ijms26041778","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}